Nimodipine (NID) is used for the prevention of ruptured intracranial aneurysms and subarachnoid haemorrhage (SAH). The objective of study using the benefits of a combined approach of polymeric nanoparticles and microneedles to fabricate NID as polymeric nanoparticles (NID-NPs) loaded in a bilayer dissolving microneedle (bDMNs) patch to enhance the delivery of drugs through skin layers as a promising noninvasive and painless delivery system, improving poor solubility and lower oral bioavailability (5–10%) owing to first-pass metabolism, which leads to frequent dosing, inconsistent clinical responses, and poor patient compliance. The NID-NPs formula was fabricated with a (1:8) drug to polymer, Soluplus®, w/w ratio and 0.25% polyvinylpyrrolidone K15 (PVPK15) using  nanoprecipitation technique. Formulas were characterized by measuring particle size (PS), polydisperse index (PDI), and entrapment efficiency (%EE). It exhibits a PS (81.78 nm) and PDI (0.046), zeta potential (-18.96 mV), and aspherical shape examined by transmission electron microscopy (TEM) with improved NID release. Moreover, the formula was designed as bilayer dissolved microneedles (bDMNs) using micromolding technique in polydimethylsiloxane (PDMS) molds. Eight microneedle (MN1-MN8) patches of polymers such as hyaluronic acid (HA), polyvinylpyrrolidone (PAPK30), polyvinyl alcohol (PVA), carboxymethylcellulose (CMC), and Pullulan (Pu) employ two plasticizers, glycerin (Gly) and polyethylene glycol 400 (PEG). The optimised formula MN2 with 10% PVA and 5% glycerin as amatrix was evaluated by measuring drug content, % moisture absorbance (%MA), weight variation, surface pH, and maximum mechanical needle strength for all MNs. Ex-vivo permeation study displayed that 80% of NID permeated in less than 2hr with a lag time of 2-3min. Insertion and mechanical studies show high resistance. Morphological study by field emission scanning electron microscopy (FE-SEM) was studied before and after the insertion into the skin, which displays sharp, strong, and uniform MNs. As a result, NP-bDMNs achieved an improvement in both solubility and drug release for transdermal drug delivery, reduced dose frequency, fewer side effects, and improved patient compliance.